CLAIMS

I Claim:

1. A composition comprising 0% to about 29% w/w of *cis*-clomiphene and about 100% to about 71% *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.

2. A composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients and wherein the ratio of *trans*-clomiphene and *cis*-clomiphene is greater than 71/29.

3. A composition consisting essentially of *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.

4. A method for treating wasting in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene is greater than 71/29.

5. A method for modulating muscle mass muscle mass in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene in said composition is greater than 71/29.

6. A method for modulating cholesterol levels in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene is greater than 71/29.

7. A method for treating lipodystrophy in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and

optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene is greater than 71/29.

8. A method for modulating lymphocyte levels in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene is greater than 71/29.

9. The method of claim 8, wherein the lymphocyte levels modulated are $CD4^+$ T lymphocyte levels are increased.

10. The method of any one of claims 4-9 wherein the composition consists essentially of an effective amount of *trans*-clomiphene or an analog thereof or a pharmaceutically effective salt or solvate thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.

11. The method of claim 10, wherein the mammal is a human.

12. The method of claim 11 wherein the human is infected with HIV

13. The method of any one of claims 4-9 where the mammal is a human.

14. The methods of claim 13 wherein the human is infected with HIV